4D Molecular Therapeutics Price Target Cut to $40.00/Share From $42.00 by B of A Securities

Dow JonesMar 10 13:03 ET · Ratings

BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating

Moomoo NewsMar 10 09:33 ET · Ratings

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration

Quiver QuantitativeMar 10 08:12 ET

Express News | 4D Molecular Therapeutics Inc - 4Front-2 Trial Expected to Initiate in Q3 2025

ReutersMar 10 08:07 ET

4DMT Enrolls First Patient In 4FRONT-1 Phase 3 Clinical Trial Of 4D-150 For Wet AMD

BenzingaMar 10 08:02 ET

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

GlobeNewswireMar 10 08:00 ET